Results 11 to 20 of about 2,468 (182)

Use of idarucizumab for emergency surgery in patients taking dabigatran [PDF]

Атеротромбоз, 2022
This article presents modern possibilities for the provision of emergency surgical care to patients with atrial fibrillation, who administered dabigatran etexilate.
O. M. Nesterova, Y. R. Lentsik, A. A. Vitik, E. D. Kosmacheva, V. I. Fetisova, M. N. Zamyatin   +5 more
doaj   +2 more sources

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran

Case Reports in Neurology, 2016
Background and Purpose: Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of ...
Valentin Held, Philipp Eisele, Christoph C. Eschenfelder, Kristina Szabo   +3 more
doaj   +2 more sources

Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study

Cardiology and Therapy, 2023
Introduction Idarucizumab, a monoclonal antibody fragment that rapidly reverses the anticoagulant effects of dabigatran, was approved in Japan in September 2016, at which time an all-case, postmarketing surveillance (PMS) study was initiated to collect ...
Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Hidesaku Asakura, Teiichi Yamane, Yukako Ogi, Takaaki Kimoto, Daisuke Nakayama   +7 more
doaj   +2 more sources

Evidence supporting idarucizumab for the reversal of dabigatran [PDF]

The American Journal of Emergency Medicine, 2016
Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers.
Pollack, Charles V.
core   +8 more sources

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke [PDF]

Frontiers in Neurology, 2019
We report a case of intravenous thrombolysis in acute ischemic stroke of anterior choroidal artery following the antagonization of dabigatran with idarucizumab.
Maren Hieber, Juergen Bardutzky
doaj   +2 more sources

Idarucizumab for a traumatic head injury patient taking dabigatran

International Journal of Emergency Medicine, 2018
Background Dabigatran is one of the four drugs currently used as a direct oral anticoagulant in Japan. Idarucizumab, which specifically targets dabigatran, was recently approved in Japan.
Shuhei Maruyama, Koichi Hayakawa, Shuji Kanayama, Hiromu Iwamura, Daiki Wada, Fukuki Saito, Yasushi Nakamori, Yasuyuki Kuwagata   +7 more
doaj   +2 more sources

Idarucizumab in dabigatran-treated patients with acute stroke: a review and clinical update [PDF]

Frontiers in Neurology
Idarucizumab is an antibody fragment specific for the immediate reversal of dabigatran anticoagulation effects. The use of idarucizumab is approved for dabigatran-treated patients suffering from life-threatening or uncontrolled bleeding and those in need
Senta Frol, Senta Frol, Janja Pretnar Oblak, Janja Pretnar Oblak, Mišo Šabovič, Mišo Šabovič, George Ntaios, Pawel Kermer, Pawel Kermer   +8 more
doaj   +3 more sources

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy [PDF]

Medicina, 2022
Background and Objectives: Thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) is used to treat acute ischemic stroke. Dabigatran is a reversible thrombin inhibitor approved for stroke prevention in patients with nonvalvular ...
Ilga Kikule, Alise Baborikina, Iveta Haritoncenko, Guntis Karelis   +3 more
doaj   +2 more sources

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Frontiers in Medicine, 2020
Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron, Nicolas Gendron, Richard Chocron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorothée Faille, Dorian Teissandier, Juliette Gay, Juliette Gay, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Ludovic Suner, Corentin Bonnet, Anne-Céline Martin, Anne-Céline Martin, Dominique Lasne, Chayma Ladhari, Aurélien Lebreton, Laurent Bertoletti, Laurent Bertoletti, Nadine Ajzenberg, Nadine Ajzenberg, Pascale Gaussem, Pascale Gaussem, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Véronique Le Cam Duchez, Alain Viallon, Pierre-Marie Roy, Pierre-Marie Roy, Agnès Lillo-le Louët, Agnès Lillo-le Louët, David M. Smadja, David M. Smadja, David M. Smadja   +39 more
doaj   +2 more sources

Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma

Trauma Case Reports, 2018
Introduction: Idarucizumab is the first effective humanized monoclonal antibody fragment developed specifically as a reversal agent for dabigatran, a Direct Oral Anticoagulant. Despite recent trials demonstrating reversal of clinically relevant bleeding,
Gail Edwards, Cristina Roman, Rondhir Jithoo, Biswadev Mitra   +3 more
doaj   +2 more sources